Literature DB >> 6223736

The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis.

M B Richter, P Woo, G S Panayi, A Trull, A Unger, P Shepherd.   

Abstract

Acute phase reactants, serum immunoglobulins and immune complexes and T cell function were measured in eight patients with active ankylosing spondylitis (AS) before and up to 3 months after three pulses of 1 g methylprednisolone. There was a two stage effect. The first stage was an early anti-inflammatory event with a fall in clinical disease activity mirrored by changes in acute phase reactants particularly prealbumin. The second stage occurred later and was an immunological event with a fall in serum IgA and IgG and a rise in mitogenic response, mixed lymphocyte response and delayed cutaneous hypersensitivity. Most of these changes returned towards pre-treatment levels by 3 months. This study has shown that pulse methylprednisolone has an immediate anti-inflammatory and a prolonged immunological effect in AS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223736      PMCID: PMC1535543     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Disease activity and serum proteins in ulcerative colitis. Immunochemical quantitation.

Authors:  I L Marner; S Friborg; E Simonsen
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

2.  Reversal of renal allograft rejection with intravenous methylprednisolone "pulse" therapy.

Authors:  N J Feduska; J G Turcotte; P W Gikas; G E Bacon; J A Penner
Journal:  J Surg Res       Date:  1972-03       Impact factor: 2.192

3.  Cellular immunity after intravenous administration of methylprednisolone.

Authors:  M L Webel; R E Ritts; H F Taswell; J V Danadio; J E Woods
Journal:  J Lab Clin Med       Date:  1974-03

4.  Effect of hydrocortisone on immunoglobulin synthesis and secretion by human peripheral lymphocytes in vitro.

Authors:  R S Smith; N A Sherman; E Middleton
Journal:  Int Arch Allergy Appl Immunol       Date:  1972

5.  Human lymphocyte antigen association in ankylosing spondylitis.

Authors:  M F Caffrey; D C James
Journal:  Nature       Date:  1973-03-09       Impact factor: 49.962

6.  Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis.

Authors:  E S Cathcart; B A Idelson; M A Scheinberg; W G Couser
Journal:  Lancet       Date:  1976-01-24       Impact factor: 79.321

7.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  The effect of in vivo hydrocortisone on subpopulations of human lymphocytes.

Authors:  A S Fauci; D C Dale
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

9.  Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone.

Authors:  W T Butler; R D Rossen
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

Review 10.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations.

Authors:  A S Fauci; D C Dale; J E Balow
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

View more
  9 in total

1.  Prediction of short-term outcome for patients with active ulcerative colitis.

Authors:  N Oshitani; T Matsumoto; Y Jinno; Y Sawa; J Hara; S Nakamura; T Arakawa; A Kitano; T Kuroki
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

Review 2.  Conventional treatments for ankylosing spondylitis.

Authors:  M Dougados; B Dijkmans; M Khan; W Maksymowych; Sj van der Linden; J Brandt
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 3.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 4.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 5.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

6.  Ankylosing spondylitis. Current drug treatment.

Authors:  J T Gran; G Husby
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 7.  Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon.

Authors:  Rbab Taha; Hadeel El-Haddad; Abdulqader Almuallim; Fatma Alshaiki; Elaf Obaid; Hani Almoallim
Journal:  Open Access Rheumatol       Date:  2017-12-15

Review 8.  Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.

Authors:  Juergen Braun; Joachim Sieper
Journal:  Arthritis Res       Date:  2002-08-06

9.  Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients Naïve for TNF blockers.

Authors:  María-Belén Bautista-Caro; Irene Arroyo-Villa; Concepción Castillo-Gallego; Eugenio de Miguel; Diana Peiteado; Chamaida Plasencia-Rodríguez; Alejandro Villalba; Paloma Sánchez-Mateos; Amaya Puig-Kröger; Emilio Martín-Mola; María-Eugenia Miranda-Carús
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.